Anika Therapeutics
Massachusetts, United States · Biotechnology, Health Care
Anika is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, includi
Key facts
- Headquarters
- Massachusetts, United States
- Employees
- 446
- Industries
- Biotechnology, Health Care
- Status
- Public (ANIK)
- Website
- anika.com
- Company page
Recent activity at Anika Therapeutics
- : Anika Therapeutics Appoints Stephen Griffin as President and CEO
- : SEC 8-K (1.01):
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On February 26, 2026, Anika Therapeutics, Inc. and Mr. David Colleran entered into a Transitional Services and General Release of Claims Agreement. Mr. Colleran will remain as Executive Vice President, General Counsel, and Corporate Secretary until May 1, 2026, unless he resigns or is terminated for cause. The agreement entitles him to continue receiving his current salary and benefits without accruing vacation, whilst also stipulating that his equity awards will vest during this period. Additionally, upon fulfilling certain conditions, he may receive further consideration as outlined in his prior Executive Retention Agreement from December 12, 2024. This arrangement underscores a significant transitional period for both Mr. Colleran and the Company, affecting his employment status and potential compensation after the anticipated separation date.
- : SEC 8-K (5.02): On January 8, 2026, the Company announced a transition in leadership, with Cheryl R. Blanchard stepping down as President and CEO effective February 1, 2026, to take on the role of Executive Chair of the Board for one year, followed by six months as Special Advisor. Steve Griffin has been appointed as the new President and CEO, effective the same day. Additionally, a Transitional Services and Separation Agreement was established on January 7, 2026, detailing Dr. Blanchard's compensation package which includes 18 months of salary paid over two years and continued eligibility for health benefits and bonuses, with an anticipated separation date of January 31, 2028. This leadership change reflects strategic adjustments aiming to guide the company through its next growth phase.
- : SEC 8-K (8.01): On November 5, 2025, Anika Therapeutics, Inc. issued a press release announcing the filing of the third and final module of its Premarket Approval application for Hyalofast, a resorbable scaffold based on hyaluronic acid, intended for use with autologous bone marrow aspirate concentrate to treat articular cartilage defects in the knee. The press release also reported outcomes from the U.S. pivotal Phase III FastTRACK clinical trial evaluating Hyalofast. This regulatory filing may significantly impact Anika's market position and future revenues, particularly in the orthopedic and regenerative medicine sectors. The event date is November 5, 2025, coinciding with the filing date.
- : Anika Completes Divestiture of Parcus Medical (date Fundz recorded it)
- : Anika Therapeutics Appoints Steve Griffin as Executive Vice President, Chief Financial Officer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Steve Griffin, President
Verified email and direct lines for Anika Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Anika Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Anika Therapeutics in the news
- Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026 - GlobeNewswire (Oct 22, 2026)
- Arthrosuface sold to Anika Therapeutics for $100m - MassDevice (Jan 14, 2020)
- Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026 - Yahoo Finance (Apr 15, 2026)
- Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study - Yahoo Finance (Nov 05, 2025)
- Anika Therapeutics (ANIK) Stock Price, News & Analysis - MarketBeat (Aug 18, 2016)
- Anika Reports Third Quarter 2026 Financial Results - GlobeNewswire (Nov 06, 2026)
- Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO - Yahoo Finance (Aug 11, 2026)
- Anika Reports Second Quarter 2025 Financial Results - GlobeNewswire (Jul 30, 2025)
Companies similar to Anika Therapeutics
- New Haven biotech firm · Biotechnology, Health Care
- Medisca · Biotechnology, Health Care
- bluebird bio · Biotechnology, Health Care
- RLS Radiopharmacies · Biotechnology, Health Care
- Meadows Behavioral Healthcare · Biotechnology, Health Care
About Anika Therapeutics: questions and answers
What does Anika Therapeutics do?
Anika is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, includi
Where is Anika Therapeutics headquartered?
Anika Therapeutics is headquartered in Massachusetts, United States.
How many employees does Anika Therapeutics have?
Anika Therapeutics has about 446 employees.
Who leads Anika Therapeutics?
Steve Griffin is a President at Anika Therapeutics.
What is the latest news on Anika Therapeutics?
On Jan 8, 2026, Anika Therapeutics Appoints Stephen Griffin as President and CEO
Is Anika Therapeutics a public company?
Yes. Anika Therapeutics is publicly traded under the ticker ANIK.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy